-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAN-711 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAN-711 in Epilepsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAN-711 in Epilepsy Drug Details: SAN-711 is under development for the treatment...
-
Product Insights
NewEpileptic Encephalopathy – Drugs In Development, 2024
Empower your strategies with our Epileptic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Epileptic encephalopathies, characterized by epileptiform abnormalities and progressive cerebral dysfunction, present in eight age-related syndromes as per the International League Against Epilepsy. Neonatal syndromes include early myoclonic encephalopathy and Ohtahara syndrome, while infancy sees West syndrome and Dravet syndrome. Childhood and adolescence encompass myoclonic status, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and epilepsy with continuous spike waves during slow wave sleep. Diagnosis entails EEG...
-
Product Insights
NewBipolar Disorder (Manic Depression) – Drugs In Development, 2024
Empower your strategies with our Bipolar Disorder (Manic Depression) – Drugs In Development, 2024 report and make more profitable business decisions. Bipolar disorder, previously known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood shifts can significantly impact a person's ability to function in daily life. The exact cause of bipolar disorder is not fully understood, but it is believed to involve a combination of...
-
Product Insights
NewChronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewInterstitial Lung Fibrosis – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-880 in Primary Immune Deficiency (PID)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-880 in Primary Immune Deficiency (PID) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-880 in Primary Immune Deficiency (PID) Drug Details: TAK-880 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NN-6434 in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NN-6434 in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NN-6434 in Atherosclerosis Drug Details:NNC-03850434 (NN-6434) is under development for the treatment of familial...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPL-108 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-108 in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPL-108 in Epithelial Ovarian Cancer Drug Details:SPL-108 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSU-6162 in Bipolar I Disorder
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OSU-6162 in Bipolar I Disorder Drug Details: OSU-6162 (PNU-96391) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSU-6162 in Bipolar II Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OSU-6162 in Bipolar II Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OSU-6162 in Bipolar II DisorderDrug Details:OSU-6162 (PNU-96391) is under development for the...